The FDA has approved a drug for patients who are 12 and older with classical Hodgkin lymphoma based on the results of a randomized clinical trial led by a UB researcher.
Gloria Aidoo-Frimpong’s invited commentary discusses the significance of a major efficacy trial involving the game Tumaini and what it signals about the future of HIV prevention for young people.